Ibuprofen enhances TRAIL-induced apoptosis through DR5 upregulation

Todo,Momoko; Horinaka,Mano; Tomosugi,Mitsuhiro; Tanaka,Ryoichi; Ikawa,Haruna; Sowa,Yoshihiro; Ishikawa,Hideki; Fujiwara,Hitoshi; Otsuji,Eigo; Sakai,Toshiyuki

doi:10.3892/or.2013.2713

Ibuprofen enhances TRAIL-induced apoptosis through DR5 upregulation

Authors:
- Momoko Todo
- Mano Horinaka
- Mitsuhiro Tomosugi
- Ryoichi Tanaka
- Haruna Ikawa
- Yoshihiro Sowa
- Hideki Ishikawa
- Hitoshi Fujiwara
- Eigo Otsuji
- Toshiyuki Sakai
View Affiliations

Affiliations: Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan, Department of Digestive Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
Published online on: August 30, 2013 https://doi.org/10.3892/or.2013.2713
Pages: 2379-2384

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous human chemoprevention studies have demonstrated that non-steroidal anti-inflammatory drugs (NSAIDs) possess chemopreventive effects against a variety of malignant tumors. However, there have been many clinical studies on aspirin, but not ibuprofen, even though ibuprofen is one of the most clinically and safely used NSAIDs showing potent anti-inflammatory effects. Moreover, we reported that many chemopreventive agents enhance the apoptosis-inducing effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is known to be crucial for cancer prevention. We, therefore, investigated whether ibuprofen enhances the cytocidal effect of TRAIL and found that ibuprofen markedly stimulated the apoptosis-inducing efficacy of TRAIL against human colon cancer HCT116 cells. As detected by western blot analysis and real-time RT-PCR, ibuprofen upregulated the expression of death receptor 5 (DR5), a TRAIL receptor. TRAIL-induced apoptosis enhanced by ibuprofen was effectively decreased by a caspase inhibitor and dominant-negative DR5. Noteworthy, co-treatment of ibuprofen with TRAIL did not enhance apoptosis in normal peripheral blood mononuclear cells (PBMCs). These results demonstrated that ibuprofen and TRAIL synergistically induced apoptosis in human colon cancer HCT116 cells but not in normal PBMCs, raising the possibility that ibuprofen may be promising as a safe chemopreventive agent against colon cancer.

View Figures

View References

1	Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet. 365:153–165. 2005. View Article : Google Scholar
2	Brasky TM, Bonner MR, Moysich KB, et al: Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control. 22:965–975. 2011. View Article : Google Scholar : PubMed/NCBI
3	Walter RB, Milano F, Brasky TM and White E: Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. J Clin Oncol. 29:2424–2431. 2011. View Article : Google Scholar
4	Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 325:1593–1596. 1991. View Article : Google Scholar : PubMed/NCBI
5	Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 348:891–899. 2003. View Article : Google Scholar : PubMed/NCBI
6	Rothwell PM, Wilson M, Elwin CE, et al: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 376:1741–1750. 2010.PubMed/NCBI
7	Rothwell PM, Wilson M, Price JF, et al: Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ishikawa H, Nakamura T, Kawano A, Gondo N and Sakai T: Chemoprevention of colorectal cancer in Japan: a brief introduction to current clinical trials. J Gastroenterol. 44:77–81. 2009. View Article : Google Scholar : PubMed/NCBI
9	Ishikawa H, Wakabayashi K, Suzuki S, et al: Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2:50–56. 2013. View Article : Google Scholar
10	Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 324:71–86. 2002. View Article : Google Scholar
11	Adams SS, McCullough KF and Nicholson JS: The pharmacological properties of ibuprofen, an anti-inflammatory, analgesic and antipyretic agent. Arch Int Pharmacodyn Ther. 178:115–129. 1969.PubMed/NCBI
12	Chan AT, Ogino S and Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 356:2131–2142. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ogino S, Kirkner GJ, Nosho K, et al: Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 14:8221–8227. 2008. View Article : Google Scholar : PubMed/NCBI
14	Kawamori T, Rao CV, Seibert K and Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:409–412. 1998.PubMed/NCBI
15	Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 352:1071–1080. 2005. View Article : Google Scholar : PubMed/NCBI
16	Baron JA, Sandler RS, Bresalier RS, et al: A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 131:1674–1682. 2006. View Article : Google Scholar : PubMed/NCBI
17	Harris RE, Beebe-Donk J and Alshafie GA: Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer. 14:2372008. View Article : Google Scholar : PubMed/NCBI
18	Schönthal AH, Chen TC, Hofman FM, et al: Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs. 17:197–208. 2008.PubMed/NCBI
19	Bonelli P, Tuccillo FM, Calemma R, et al: Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: a gene pathway analysis. Pharmacogenomics J. 11:412–428. 2011. View Article : Google Scholar : PubMed/NCBI
20	Greenspan EJ, Madigan JP, Boardman LA and Rosenberg DW: Ibuprofen inhibits activation of nuclear β-catenin in human colon adenomas and induces the phosphorylation of GSK-3β. Cancer Prev Res. 4:161–171. 2011.
21	Harris RE, Beebe-Donk J, Doss H and Burr Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (Review). Oncol Rep. 13:559–583. 2005.
22	Taniguchi H, Horinaka M, Yoshida T, et al: Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules. Mol Cancer Ther. 11:2294–2300. 2012. View Article : Google Scholar : PubMed/NCBI
23	Taniguchi H, Yoshida T, Horinaka M, et al: Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res. 68:8918–8927. 2008. View Article : Google Scholar
24	Yoshida T, Maoka T, Das SK, et al: Halocynthiaxanthin and peridinin sensitize colon cancer cell lines to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Res. 5:615–625. 2007. View Article : Google Scholar : PubMed/NCBI
25	Horinaka M, Yoshida T, Shiraishi T, et al: The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther. 5:945–951. 2006. View Article : Google Scholar : PubMed/NCBI
26	Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1993.PubMed/NCBI
27	Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
28	Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 5:876–885. 2005. View Article : Google Scholar : PubMed/NCBI
29	Soria JC, Smit E, Khayat D, et al: Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 28:1527–1533. 2010. View Article : Google Scholar : PubMed/NCBI
30	Leong S, Cohen RB, Gustafson DL, et al: Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol. 27:4413–4421. 2009. View Article : Google Scholar : PubMed/NCBI
31	Zerafa N, Westwood JA, Cretney E, et al: Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol. 175:5586–5590. 2005. View Article : Google Scholar : PubMed/NCBI
32	Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M and Sakai T: Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene. 23:6261–6271. 2004. View Article : Google Scholar
33	Kim KM, Song JJ, An JY, Kwon YT and Lee YJ: Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. J Biol Chem. 49:41047–41056. 2005. View Article : Google Scholar : PubMed/NCBI
34	Braun FK, Al-Yacoub N, Plötz M, Möbs M, Sterry W and Eberle J: Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand. J Invest Dermatol. 132:429–439. 2012. View Article : Google Scholar : PubMed/NCBI
35	Huang Y, He Q, Hillman MJ, Rong R and Sheikh MS: Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res. 61:6918–6924. 2001.
36	Sinicrope FA and Penington RC: Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther. 4:1475–1483. 2005. View Article : Google Scholar : PubMed/NCBI
37	Heijink DM, Jalving M, Oosterhuis D, et al: TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. J Pathol. 223:378–389. 2011. View Article : Google Scholar : PubMed/NCBI
38	Ricchi P, Zarrilli R, Di Palma A and Acquaviva AM: Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer. 88:803–807. 2003. View Article : Google Scholar : PubMed/NCBI
39	Sheng H, Shao J, Kirkland SC, et al: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 99:2254–2259. 1997. View Article : Google Scholar : PubMed/NCBI
40	Bjarnason I: Gastrointestinal safety of NSAIDs and over-the-counter analgesics. Int J Clin Pract (Suppl). 178:37–42. 2013. View Article : Google Scholar : PubMed/NCBI
41	Schnitzer TJ, Burmester GR, Mysler E, et al: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 364:665–674. 2004. View Article : Google Scholar
42	Lugardon S, Lapeyre-Mestre M and Montastruc JL: Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. Eur J Clin Pharmacol. 60:673–677. 2004. View Article : Google Scholar : PubMed/NCBI
43	Van GE, Jones JK, Moore N, Parc JM, Wall R and Schneid H: A large simple clinical trial prototype for assessment of OTC drug effects using patient-reported data. Pharmacoepidemiol Drug Saf. 14:249–255. 2005. View Article : Google Scholar : PubMed/NCBI
44	Horinaka M, Yoshida T, Kishi A, et al: Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells. FEBS Lett. 584:577–582. 2010. View Article : Google Scholar : PubMed/NCBI